Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 18;6:84. doi: 10.1038/s41541-021-00345-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A 10 μg dose of PfCSP mRNA-LNP1, TriLink, and UPenn, prime:boost (2x) or prime:boost:boost (3x) regimen on a 3-week interval was tested against Pb(ANKA)-PfCSP (Wellcome) transgenic parasites (N = 15 per group for TriLink 3x and naïve controls) (N = 10, UPenn 3x) (N = 5 per group for TriLink 2x and LNP1 alone) with 1000 sporozoites injected intravenously, 2 weeks post final immunization. a Kaplan–Meier curves report the percent survival of challenged mice. Efficacy was calculated against the negative controls (LNP1 alone and naïve controls). Survival was defined as mice without detectable parasitemia by thin blood smear by day 14. b Functional activity of the antibodies was quantified by the ILSDA using pooled mouse serum of each group. Inhibition was calculated relative to the mean of sporozoite invasion in the absence of mouse serum. Data are reported as the mean of assay replicates. c r-PfCSP ELISA (N = 20 per group for UPenn 3x, TriLink 2x) (N = 19, TriLink 3x) (N = 10, LNP1 alone), d fine specificity ELISA against the (NANP)₆ repeat peptide (N = 20 per group for UPenn 3x, TriLink 2x) (N = 19, TriLink 3x), e fine specificity ELISA are reported as the ratio of the (NANP)₆ titer to the α-TSR titer (N = 20, UPenn) (N = 17 per group for TriLink 3x, TriLink 2x), f the ratio of r-PfCSP IgG subclass titers for IgG1 and IgG2a (N = 20, UPenn 3x) (N = 18, TriLink 3x) (N = 19, TriLink 2x) and g r-PfCSP avidity ELISA (N = 20, UPenn 3x) (N = 19 per group for TriLink 3x, TriLink 2x). Uninfected, infected, and unchallenged mice are represented by black, red, and gray symbols, respectively. Data in the bar graph are reported as the GM with 95% CI. All statistical analyses were performed using one-way ANOVA on ranks, Kruskal–Wallis post hoc Dunn’s multiple comparison test (**p < 0.01; ****p < 0.0001).